Log in

Relevant bibliographies by topics / Chemotherapeutic and Targeted Therapies / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Chemotherapeutic and Targeted Therapies.

Dissertations / Theses on the topic 'Chemotherapeutic and Targeted Therapies'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'Chemotherapeutic and Targeted Therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Tucker, Catherine Amanda. "Targeted therapies in mantle cell lymphoma." Thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/922.

Full text

Abstract:

Mantle cell lymphoma (MCL) is characterized by the presence of the t(11 ;14)(g13 ;g32) translocation which results in cyclin Dl over-expression. MCL is one of the most difficult lymphoproliferative disorders to manage with a median survival rate of 43 months from diagnosis. The poor prognosis associated with MCL is due in large part to its late classification as a separate clinical entity leading to a dearth in available pre-clinical models. The specific objectives of the research described in this thesis were (1) to establish MCL preclinical models of disease and (2) to evaluate deregulated c

APA, Harvard, Vancouver, ISO, and other styles

2

Yau, Chung-cheung, and 邱宗祥. "Molecular targeted therapies in advanced hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48421145.

Full text

Abstract:

With the recent advances in the knowledge of hepato-carcinogenesis, there has been encouraging development in the molecular targeted therapy for patients with advanced hepatocellular carcinoma (HCC). Sorafenib, an anti-angiogenic multi-targeted receptor tyrosine kinase inhibitor, has become the standard of treatment in HCC patients with Child-Pugh A cirrhosis. Nevertheless, the benefits and safety profile of sorafenib in the majority of the unselected advanced HCC patients and other patient subgroups are still unclear. More importantly, the survival benefit associated with sorafenib use is ge

APA, Harvard, Vancouver, ISO, and other styles

3

Zaman, Noreen Tasneem. "Targeted and stimuli-responsive polymers as chemotherapeutic delivery systems." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/43217.

Full text

Abstract:

Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2008.<br>Includes bibliographical references.<br>Successful administration of chemotherapeutic agents for cancer treatment requires a balance between the efficacy and the safety of the drug. This often limits physicians to a very narrow therapeutic window. To avoid the harmful side-effects, chemotherapeutic agents may be administered at a suboptimal dose. This is not only a less effective treatment, but can lead to the development of drug resistance by cancerous cells. The therapeutic window can be increased

APA, Harvard, Vancouver, ISO, and other styles

4

Guerreiro-Lucas, Luciano Andre. "Longitudinal intravital evaluation of tumour vasculature targeted therapies." Thesis, University of Nottingham, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.495592.

Full text

Abstract:

Tumour growth and metastasis are dependent on the formation and maintenance of a dedicated microvascular network. Angiostatin4.5 (AS4.5) is a naturally occurring anti-angiogenic agent known to inhibit angiogenesis in vitro and tumour growth in vivo.

APA, Harvard, Vancouver, ISO, and other styles

5

Leite, Diana Moreira. "Peptide nanomaterials as targeted endocrine therapies for glioblastoma." Thesis, University of Portsmouth, 2017. https://researchportal.port.ac.uk/portal/en/theses/peptide-nanomaterials-as-targeted-endocrine-therapies-for-glioblastoma(15707f91-4dd4-4220-bf7e-bb008a65b632).html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bolin, Sara. "Mechanisms of Medulloblastoma Dissemination and Novel Targeted Therapies." Doctoral thesis, Uppsala universitet, Neuroonkologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300907.

Full text

Abstract:

Medulloblastomas are the most frequent malignant childhood brain tumors, arising in the posterior fossa of children. The overall 5-year survival is 70%, although children often suffer severe long-term side effects from standard medical care. To improve progression-free survival and quality of life for these children, finding new therapeutic targets in medulloblastoma is imperative. Medulloblastoma is divided in to four molecular subgroups (WNT, SHH, Group 3 and Group 4) based on key developmental pathways essential for the initiation and maintenance of tumor development. The MYC family of prot

APA, Harvard, Vancouver, ISO, and other styles

7

Romanus, Dorothy. "The Value of Targeted Therapies in Lung Cancer." Thesis, Harvard University, 2014. http://nrs.harvard.edu/urn-3:HUL.InstRepos:13070030.

Full text

Abstract:

The goal of this dissertation was to examine the realized value of targeted therapies in routine care and to identify opportunities for improving the return on medical spending for these technologies. Chapter 1 investigated the value of targeted therapies in lung cancer patients who were treated in routine care. This observational, claims-based analysis used propensity score, and instrumental variable methods, combined with a Kaplan Meier Sample Average estimator to calculate lifetime costs and life expectancy. An incremental comparison showed that the realized value of targeted therapies

APA, Harvard, Vancouver, ISO, and other styles

8

Fallaha, Sora. "Targeted Molecular Therapies for HPV-driven Cervical Cancers." Thesis, Griffith University, 2017. http://hdl.handle.net/10072/370595.

Full text

Abstract:

The report by zur Hausen in 1980 linking Human papilloma virus (HPV) infections to major cancers was a key turning point in the HPV-driven cancer discovery era. HPV are doublestranded DNA viruses that belong to the Papillomaviridae family. Most HPV infections resolve spontaneously, or may cause indications (such as warts, anogenital, oro-laryngeal and -pharyngeal papillomas) that are easy to treat. Persistent and untreated infections with certain types of high risk (HR) HPV, particularly types 16 and 18, increase the risk for the development of cancer, such as cervical cancer (CC). In fact, hi

APA, Harvard, Vancouver, ISO, and other styles

9

Stephen, Renu M. "Magnetic Resonance Imaging Biomarkers For Targeted Cancer Therapies." Diss., The University of Arizona, 2008. http://hdl.handle.net/10150/194845.

Full text

Abstract:

In 2007, there will be an estimated 178,480 new cases of breast cancer diagnosed in women in the United States. The elucidation of the vast heterogeneity of individual tumors has led to a paradigm shift from a one-size fits all treatment strategy to more individualized treatment based on the molecular profile of the tumor. Identifying biomarkers that respond to or predict the action of drugs is important in identifying efficacious targets and drugs that will improve clinical outcome. To examine this, we first identified two breast cancer cell lines (ACC-3199 and ACC-3171) from a panel of lo

APA, Harvard, Vancouver, ISO, and other styles

10

Karandish, Fataneh. "Targeted Stimuli-Responsive Carriers for Efficient Delivery of Chemotherapeutic Drugs." Diss., North Dakota State University, 2017. https://hdl.handle.net/10365/26706.

Full text

Abstract:

Chemotherapeutic agents for treating various cancers show considerable side effects and toxicity. Often cancer relapses after initial response to the chemotherapy. Tumor cells are heterogeneous and have the progenitor stem cells which can renew, causing the relapse of the disease. To overcome drug resistance, metastasis, and relapse in cancer, targeted therapy is a promising approach. Targeted delivery of chemotherapeutic agents decrease toxicity and improve efficacy for cancer treatment. We have designed targeted, stimuli-responsive echogenic polymeric vesicles (polymersomes) to not only tran

APA, Harvard, Vancouver, ISO, and other styles

11

Esteve, Arenys Anna. "Innovative targeted therapies for chemorefractory B-cell non-Hodgkin lymphomas." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/565937.

Full text

Abstract:

Lymphomas are a heterogeneous group of tumors characterized by the proliferation of lymphocytes predominantly in lymphoid structures but also in extranodal tissues. More than 90% of patients are afflicted by lymphomas of B-cell origin. The current World Health Organization (WHO) classification of hematopoietic and lymphoid tumors categorizes B-cell neoplasms in more than 40 distinct disease entities, according to a combination of the morphology, immunophenotype, genetic, molecular and clinical features. Each entity has its own clinical course and requires specific treatments. The chara

APA, Harvard, Vancouver, ISO, and other styles

12

Serna, Romero Naroa. "Development of self-assembling protein only nanoparticles for targeted therapies." Doctoral thesis, Universitat Autònoma de Barcelona, 2018. http://hdl.handle.net/10803/662777.

Full text

Abstract:

Las medicinas innovadoras demandan con urgencia nuevos vehículos funcionales para la entrega dirigida de fármacos convencionales y novedosos, preferentemente en forma de nanopartículas. Los materiales nanoestructurados mejoran la biodistribución y la penetración celular, lo que les convierten en transportadores eficaces de fármacos, que con un rango de tamaño entre 6 y 100 nm escapan al filtrado renal. La arquitectura de estos nanoconjugados vehículo-fármaco debe ser lo suficientemente estable para permitir la circulación sistémica y la entrega específica en los tejidos diana, reduciendo as

APA, Harvard, Vancouver, ISO, and other styles

13

Giménez, Carabaza Neus. "Targeted therapies in CLL. New drugs against CLL recurrent mutations." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/668219.

Full text

Abstract:

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western countries. It is currently an incurable disease. CLL is a B-lymphoid neoplasm in which the microenvironment plays a key role in the development and evolution of the disease. The complete sequencing of 500 CLL patients described the presence of recurrent mutations, the study of which could improve clinical interventions in the management of this neoplasm and design specific treatments for each patient. In this dissertation we have studied two of the most frequently mutated pathways in CLL: RAS-BRAF-MAPK-ERK and TLR-M

APA, Harvard, Vancouver, ISO, and other styles

14

Miniotis, Maria Falck. "Evaluation of MRS detectable metabolic markers of MEK1/" targeted therapies." Thesis, University of London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.533141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Martinez, Chanza Maria. "CYTOTOXIC AGENTS AND MOLECULAR TARGETED THERAPIES IN GENITOURINARY TRACT TUMORS." Doctoral thesis, Universite Libre de Bruxelles, 2021. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/323785.

Full text

Abstract:

Les agents cytotoxiques et les thérapies moléculaires ciblées sont l’un des piliers du traitement des patients atteints de tumeurs génito-urinaires. Cependant, il existe de nombreuses situations médicales pour lesquelles l’on manque d’options thérapeutiques standards dans la pratique clinique. Ce travail de recherche clinique vise à identifier et comprendre de telles situations ainsi qu'à essayer d'améliorer les résultats cliniques de ces sous-groupes de patients. Afin d'atteindre cet objectif, différents projets cliniques ont été développés.La première partie de cette thèse est consacrée à l'

APA, Harvard, Vancouver, ISO, and other styles

16

Tavallai, Mehrad. "INTRODUCING NOVEL COMBINATORIAL TARGETED THERAPIES IN MULTIPLE TYPES OF CANCER." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4088.

Full text

Abstract:

The cancers of liver, colon and breast are amongst the top five most prevalent and most fatal worldwide. As the Raf/MEK/ERK pathway is frequently deregulated in hepatocellular carcinoma (HCC), sorafenib, a Raf kinase inhibitor, became the first systemic therapy approved for the treatment of patients with HCC. However, sorafenib only produced modest effects with low response rates in the clinic. Similarly, regorafenib, which was approved for the treatment of metastatic colorectal cancer (CRC), has had a poor response rate in the clinic. Since phosphodiesterase type 5 has been reported to be ove

APA, Harvard, Vancouver, ISO, and other styles

17

Dawson, Jesse. "Prevention of stroke risk stratification and targeted and novel therapies /." Thesis, Connect to e-thesis, 2009. http://theses.gla.ac.uk/851/.

Full text

Abstract:

Thesis (MD.) - University of Glasgow, 2009.<br>MD. thesis submitted to Division of Cardiovascular and Medical Sciences, University of Glasgow, 2009. Includes bibliographical references. Print version also available.

APA, Harvard, Vancouver, ISO, and other styles

18

Shen, Yandong. "The Chronic Lymphocytic Leukemia (CLL) Microenvironment and Novel Targeted Therapies." Thesis, The University of Sydney, 2019. http://hdl.handle.net/2123/20805.

Full text

Abstract:

Activation of the B-cell receptor (BCR), and subsequent signalling via the Bruton's tyrosine kinase (BTK), phosphoinositide-3 kinase (PI3K) and mitogen-activated protein kinase (MAPK), plays a significant role in the pathogenesis of CLL. This thesis aimed to better understand the role of the CLL microenvironment and to investigate novel treatment strategies for targeting CLL cells in the lymph nodes or bone marrow. We demonstrated using the DotScan cluster of differentiation (CD) antibody microarray, that immunophenotypic changes induced on CLL cells by co-culture with fibroblasts expressing

APA, Harvard, Vancouver, ISO, and other styles

19

Heisey, Daniel A. R. "TARGETED THERAPIES FOR EWSR1-FLI1 TRANSLOCATED EWING FAMILY OF TUMORS." VCU Scholars Compass, 2019. https://scholarscompass.vcu.edu/etd/5950.

Full text

Abstract:

The EWSR1-FLI1 t(11;22)(q24;q12) translocation is the pathognomonic genomic alteration in 85% of the Ewing Family of Tumors (EWFT) a malignancy of the bone and the surrounding tissue, predominantly affecting children and adolescents. This translocation results in the formation of a chimeric oncoprotein which acts as an aberrant transcription factor that is currently not pharmaceutically druggable, driving the need for more effective targeted therapies. The EWSR1-FLI1 translocation induces a variety of changes including dysregulation of the epigenome and altered gene expression to drive tumo

APA, Harvard, Vancouver, ISO, and other styles

20

EPISTOLIO, SAMANTHA. "Targeted therapies in lung adenocarcinomas: new methodologies and new markers." Doctoral thesis, Università del Piemonte Orientale, 2018. http://hdl.handle.net/11579/103214.

Full text

Abstract:

Il cancro ai polmoni è la patologia neoplastica con il tasso di mortalità più elevato. L’adenocarcinoma (AC), che rappresenta il 60% dei tumori polmonari non a piccole cellule (NSCLC), è l’istotipo più diffuso e attaualmente viene trattato mediante resezione chirurgica combinata con un regime chemioterapico basato su platino (Pt) abbinato ad una coppia di molecole citotossiche. Con lo scopo di risolvere gli svantaggi del trattamento chemioterapico, negli ultimi anni sono stati sviluppati farmaci a bersaglio molecolare. Le terapie molecolari maggiormente utilizzate per gli AC polmonari sono gli

APA, Harvard, Vancouver, ISO, and other styles

21

CUPPINI, LUCIA. "Antiangiogenic therapies for malignant gliomas: new markers for targeted treatment." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2012. http://hdl.handle.net/10281/28473.

Full text

Abstract:

Bevacizumab has shown activity in different tumor types, including high grade gliomas (HGG). However, the use of bevacizumab and other antiangiogenic drugs in the clinical setting limited by the lack of markers to predict responses. We report that the combined treatment with bevacizumab and irinotecan is effective in recurrent HGG patients, particularly in those with local disease, with mild toxicity. Median OS and PFS were 33 and 18 weeks, respectively. PFS at 6 and 12 months were 32% and 12%. OS at 6 months was 60%. Patients with distant intracerebral disease or leptomeningeal dissemination

APA, Harvard, Vancouver, ISO, and other styles

22

Sánchez, García Laura. "Engineering all-in-one protein-based nanoparticles for targeted cancer therapies." Doctoral thesis, Universitat Autònoma de Barcelona, 2019. http://hdl.handle.net/10803/667195.

Full text

Abstract:

Actualmente, las terapias convencionales contra el cáncer están lejos de ser ideales en cuanto a eficacia. Los fármacos actuales, formados por pequeños compuestos químicos se distribuyen indistintamente por todo el organismo, generando elevada toxicidad sistémica y dando lugar a efectos secundarios en tejidos sanos. En este contexto, la nanomedicina es una disciplina emergente que ofrece alternativas prometedoras para el desarrollo de terapias innovadoras y mejoradas contra el cáncer. Siendo materiales especialmente versátiles, las proteínas recombinantes están ganando mucho interés en el áre

APA, Harvard, Vancouver, ISO, and other styles

23

Thangavelu, Amudha. "Targeted therapies in endomental cancer - in vitro and in vivo models." Thesis, University of Leeds, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.531515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bodey, Rachel Kay. "The combination of dosimetry for targeted radionuclide and external beam therapies." Thesis, Institute of Cancer Research (University Of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.417601.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rodrigues, Tiago André Moura. "Current options in breast cancer targeted therapies: life after HER-2." Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2009. http://hdl.handle.net/10216/53412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Rodrigues, Tiago André Moura. "Current options in breast cancer targeted therapies: life after HER-2." Dissertação, Instituto de Ciências Biomédicas Abel Salazar, 2009. http://hdl.handle.net/10216/53412.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

CONTINO, GIANMARCO. "Rational design of targeted therapies for Pancreatic adenocarcinoma in K-ras GEMMs." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2014. http://hdl.handle.net/10281/55465.

Full text

Abstract:

L’adenocarcinoma pancreatico e’ una delle neoplasie con piu’ alta mortalita’ nei paesi occidentali, con una sopravvivenza media di 6 mesi e una percentuale estremamente bassa di sopravvivenza a lungo termine. L’evento principale nello sviluppo dell’adenocarcinoma pancreatico e’ la mutazione del gene KRAS, che tuttavia e’ particolarmente difficile da colpire a livello molecolare. Strategie terapeutiche piu’ efficaci per l’adenocarcinoma pancreatico possono derivare dall’impiego di terapie molecolari. L'obiettivo di questo lavoro e’ quello di identificare nuovi meccanismi e molecolari e strateg

APA, Harvard, Vancouver, ISO, and other styles

28

Campbell, Lynn Rachel. "The role of her-targeted therapies on chemosensization in gastro-oesphageal cancer cells." Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534707.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Randall, Adrian Joseph. "A systems approach to uncovering the adaptive response of cancer to targeted therapies." Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/72967.

Full text

Abstract:

Thesis (S.M.)--Massachusetts Institute of Technology, Computational and Systems Biology Program, 2012.<br>Cataloged from PDF version of thesis.<br>Includes bibliographical references (p. 47-53).<br>Tyrosine kinase inhibitors have significant promise in the fight to develop agents that can target cancer in a tumor-specific manner. A number of drugs have been and are currently in development to inhibit specific kinases that can mediate uncontrolled proliferation; however, an unfortunate eventuality for most patients receiving these treatments is the development of resistance that renders these d

APA, Harvard, Vancouver, ISO, and other styles

30

Kakavand, Hojabr. "Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17184.

Full text

Abstract:

The previously dismal prospects of patients with advanced stage metastatic melanoma have greatly improved in recent years. Enhanced understanding of both the pathogenesis of melanoma and its molecular drivers, as well as the importance and regulation of anti-tumour immune responses, have provided new therapeutic opportunities for melanoma patients. There are two major distinct categories of systemic treatments with activity for patients with metastatic melanoma: (1) targeted therapies, which act to inhibit the oncogenes that drive the aberrant growth and dissemination of the tumour; and (2) im

APA, Harvard, Vancouver, ISO, and other styles

31

CHO, DOAH. "A framework for extrapolating evidence for targeted therapies in rare biomarker-defined cancers." Thesis, The University of Sydney, 2022. https://hdl.handle.net/2123/29831.

Full text

Abstract:

This thesis aimed to develop an approach to assess the clinical benefit of targeted therapies for rare cancers. Despite claims that targeted therapies are superior based on strong biological rationale, a review of randomised controlled trials (RCTs) showed the clinical benefit of targeted therapies is only modest when compared with chemotherapy (Chapter 2). However, conducting adequately powered RCTs using endpoints that capture net clinical benefit may be infeasible in rare cancers. Using molecular profiling, even common cancers are being reclassified into rare biomarker-defined diseases. Man

APA, Harvard, Vancouver, ISO, and other styles

32

Zasso, Jacopo. "Identification of REST-Regulated Molecular Circuitries and Targets Exploitable for hGSCs-Targeted Therapies." Doctoral thesis, Università degli studi di Trento, 2018. https://hdl.handle.net/11572/369006.

Full text

Abstract:

Glioblastoma (GBM) represents the most frequent and lethal cancer affecting the central nervous system for which no cure is currently available. The presence of Glioma Stem Cells (GSCs) has been proposed to be at the root of therapeutic failures due to their intrinsic abilities of escaping common treatments and relapsing the pathology. Thus, advances in therapeutic options may derive from the manipulation of mechanisms controlling the GSCs self-renewal, survival and functions. RE1-Silencing Transcription Factor (REST) is a master repressor of neuronal developmental programme in non-neuronal li

APA, Harvard, Vancouver, ISO, and other styles

33

Zasso, Jacopo. "Identification of REST-Regulated Molecular Circuitries and Targets Exploitable for hGSCs-Targeted Therapies." Doctoral thesis, University of Trento, 2018. http://eprints-phd.biblio.unitn.it/3357/1/JZ_PhD_Thesis.pdf.

Full text

Abstract:

Glioblastoma (GBM) represents the most frequent and lethal cancer affecting the central nervous system for which no cure is currently available. The presence of Glioma Stem Cells (GSCs) has been proposed to be at the root of therapeutic failures due to their intrinsic abilities of escaping common treatments and relapsing the pathology. Thus, advances in therapeutic options may derive from the manipulation of mechanisms controlling the GSCs self-renewal, survival and functions. RE1-Silencing Transcription Factor (REST) is a master repressor of neuronal developmental programme in non-neuronal li

APA, Harvard, Vancouver, ISO, and other styles

34

ULTIMO, Simona. "Inhibition of the PI3K/Akt/mTOR signaling pathway as a therapeutic target for Acute Lymphoblastic Leukemia." Doctoral thesis, Università degli studi di Ferrara, 2018. http://hdl.handle.net/11392/2487845.

Full text

Abstract:

Acute Lymphoblastic Leukemia (ALL) is a malignant disorder characterized by the abnormal clonal proliferation of B-cell progenitors (B-ALL) or immature stage thymocytes (T-ALL). Constitutive activation of the PI3K/Akt/mTOR network is a common feature of B- and T-ALL, influencing cell growth and survival. The PI3K/Akt/mTOR inhibitors are currently being developed for clinical use either as single agents or in combination with conventional chemotherapy for T-ALL patient treatment. In this study it has been investigated the effects of a panel of PI3K/Akt/mTOR inhibitors on healthy human CD4+ T-c

APA, Harvard, Vancouver, ISO, and other styles

35

Pavlik, Aaron, Phillip Schneider, and Cheryl Cropp. "Proposing Molecularly Targeted Therapies Using an Annotated Drug Database Querying Algorithm in Cutaneous Melanoma." The University of Arizona, 2015. http://hdl.handle.net/10150/614155.

Full text

Abstract:

Class of 2015 Abstract<br>Objectives: The aim of this study was to develop a computational process capable of hypothesizing potential chemotherapeutic agents for the treatment of skin cutaneous melanoma given an annotated chemotherapy molecular target database and patient-specific genetic tumor profiles. Methods: Aberrational profiles for a total of 246 melanoma patients indexed by the Cancer Genome Atlas (TCGA) for whom complete somatic mutational, mRNA expression, and protein expression data was available were queried against an annotated targeted therapy database using Visual Basic for App

APA, Harvard, Vancouver, ISO, and other styles

36

Kouadio, Ange S. "Exploring the therapeutic potential of novel molecular targeted therapies in treating human ovarian cancer." Click here for download, 2008. http://proquest.umi.com/pqdweb?did=1650501211&sid=2&Fmt=2&clientId=3260&RQT=309&VName=PQD.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Fenton, Audrey C. "The role of oncogenic kras as a determinant of response to EGER?HER2 targeted therapies." Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534743.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Cartaxo, Ana L. "Tumor microenvironment models: ex vivo, in vitro and in silico approaches to address targeted therapies." Doctoral thesis, Universidade Nova de Lisboa, Instituto de Tecnologia Química e Biológica António Xavier, 2020. http://hdl.handle.net/10362/105645.

Full text

Abstract:

"Cancer is the second leading cause of mortality worldwide, despite the extraordinary advances in the last two decades due to the development of targeted therapies. These target particular molecules required for cell growth and tumorigenesis; nonetheless, de novo or acquired resistance to therapy often lead to patient relapse and disease progression. There is cumulating evidence supporting the importance of tumor microenvironment (TME)-driven mechanisms in cancer progression and drug resistance. Therefore, there is a need for cancer models in which crit

APA, Harvard, Vancouver, ISO, and other styles

39

Hansom, Donald. "The effects of nanopattern surface technology and targeted metabolic therapies on orthopaedic implant related infections." Thesis, University of Glasgow, 2017. http://theses.gla.ac.uk/7917/.

Full text

Abstract:

Bacterial biofilm infections cause significant morbidity in orthopaedic joint replacement. One of the most common bacteria in orthopaedic prosthetic infections is Staphylococcus aureus. Infection causes implant failure due to bacterial adherence and subsequent biofilm production. Nanotopography refers to the topography of a surface at the nanometre level and has major effects on cell behaviour. Studies suggest that surface nanotopography impacts the differential ability of staphylococci species to adhere, and may reduce orthopaedic implant infection rate. This research thesis focuses on bacter

APA, Harvard, Vancouver, ISO, and other styles

40

Mao, Yicheng. "Monoclonal Antibody and Liposomal Nanoparticle-based Targeting Therapies for Chronic Lymphocytic Leukemia." The Ohio State University, 2012. http://rave.ohiolink.edu/etdc/view?acc_num=osu1354299911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

FATIMA, RIZWAN NARJIS. "Targeting the integrated stress response (ISR) as a therapeutic option for chronic lymphocytic leukemia." Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/25009.

Full text

Abstract:

The mechanisms behind development of drug resistance in B-Chronic lymphocytic leukemia (CLL) are unclear and need research to find better treatment options. BCR signalling lead to activation of MEK/ERK, PI3K/AKT pathways and reduced apoptosis through BCL2 pathway. Studies have shown that integrated stress response (ISR) also stimulates oncogenic signalling. This thesis was aimed at understanding the mechanisms of action of some novel drugs that can inhibit CLL proliferation by targeting the BCR and ISR pathways in presence of an in vitro CLL tumor microenvironment (TME). We have shown indu

APA, Harvard, Vancouver, ISO, and other styles

42

Vasista, Anuradha. "Estimating and communicating survival times to patients with incurable cancer who are treated with targeted therapies." Thesis, The University of Sydney, 2020. https://hdl.handle.net/2123/22601.

Full text

Abstract:

The aim of this thesis was to help oncologists estimate and communicate survival times to patients with incurable cancer receiving targeted therapies. For patients with incurable cancer receiving chemotherapy, simple multiples of an overall survival (OS) curve’s median accurately estimate its percentiles corresponding to worst case (90th percentile, 1/4 x median OS), typical (25th to 75th percentile, 1/2 to 2 x median OS) and best case scenarios (10th percentile, >3 x median OS) for survival. We aimed to determine if this principle can be applied to patients with incurable cancer receiving tar

APA, Harvard, Vancouver, ISO, and other styles

43

Yu, Ming Threadgill David W. "The importance of ERBB receptor tyrosine kinase signaling in colorectal cancer implications for EGFR-targeted therapies /." Chapel Hill, N.C. : University of North Carolina at Chapel Hill, 2008. http://dc.lib.unc.edu/u?/etd,1530.

Full text

Abstract:

Thesis (Ph. D.)--University of North Carolina at Chapel Hill, 2008.<br>Title from electronic title page (viewed Sep. 16, 2008). "... in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Oral Biology Program, School of Dentistry." Discipline: Oral Biology; Department/School: Dentistry.

APA, Harvard, Vancouver, ISO, and other styles

44

Arnedos, Ballester Monica. "Personalized Medicine and Biomarker Discovery to Targeted Therapies in Breast Cancer : Focus on CDK4/6 Inhibitors." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS181.

Full text

Abstract:

L’avènement du séquençage haut débit a mis en lumière l’hétérogénéité des cancers du sein qui peuvent être groupés en fonction d’altérations moléculaires spécifiques qui sont pour certaines à la base de thérapies ciblées dans le cadre de la médecine personnalisée. Néanmoins de nombreuses complications viennent compromettre le succès thérapeutique de ces approches. En effet, l’une des thérapies ciblées les plus efficaces développées récemment, les inhibiteurs de CDK4/6, sont prescrits chez tous les patients HR+/HER aux stades avancés de la maladie alors même qu’aucun biomarqueur n’a pour l’heur

APA, Harvard, Vancouver, ISO, and other styles

45

Tousignant, Kaylyn Davis. "Investigation of metabolic rewiring in prostate cancer cells during the adaptive response to androgen-targeted therapies." Thesis, Queensland University of Technology, 2020. https://eprints.qut.edu.au/180822/1/Kaylyn_Tousignant_Thesis.pdf.

Full text

Abstract:

The development of therapy resistance is a major obstacle in the successful treatment of advanced prostate cancer. This thesis investigated mechanisms that help drive therapy resistance and discovered that prostate cancer cells can utilise different metabolic pathways in order to become resistant to current therapies. This project also explores new therapeutic strategies to use in combination with current treatments to help fight disease progression and improve outcomes for men with prostate cancer.

APA, Harvard, Vancouver, ISO, and other styles

46

Tower, Robert J. [Verfasser]. "Bisphosphonates : from bone-targeted therapies to molecular imaging agents of in vivo bone metabolism / Robert J. Tower." Kiel : Universitätsbibliothek Kiel, 2018. http://d-nb.info/1155166019/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Hu, Qiuhua. "Investigating prostate tumour vasculature and oxygenation status in response to androgen-targeted therapies using photoacoustic-ultrasound imaging." Thesis, Queensland University of Technology, 2022. https://eprints.qut.edu.au/228679/8/Qiuhua_Hu_Thesis.pdf.

Full text

Abstract:

This project provides a holistic view of changes in the prostate cancer microenvironment in response to androgen targeted therapies. Oxygen saturation and total haemoglobin were monitored using the ultrasound and photoacoustic imaging capabilities of the VEVO LAZR system (FUJIFILM Visual Sonics Inc) and compared with measuring hypoxic and vascular markers using conventional protein and gene expression techniques. Understanding the effects of castration and enzalutamide on the vasculature and oxygenation status of prostate cancer subcutaneous xenografts has the potential to reveal novel mechani

APA, Harvard, Vancouver, ISO, and other styles

48

Costanzini, Anna <1990&gt. "Bioenergetics of cancer cells in anoxia and role of the miRNAs in melanoma resistance to targeted therapies." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2019. http://amsdottorato.unibo.it/8810/1/Costanzini_Anna_tesi.pdf.

Full text

Abstract:

Tumours are characterized by a metabolic rewiring that helps transformed cells to survive in harsh conditions. The endogenous inhibitor of the ATP-synthase IF1 is overexpressed in several tumours and it has been proposed to drive metabolic adaptation. In ischemic normal-cells, IF1 acts limiting the ATP consumption by the reverse activity of the ATP-synthase, activated by ΔΨm collapse. Conversely, IF1 role in cancer cells is still unclear. It has been proposed that IF1 favours cancer survival by preventing energy dissipation in low oxygen availability, a frequent condition in solid tumours. Ou

APA, Harvard, Vancouver, ISO, and other styles

49

Arora, Sameer. "USE OF ORAL CHEMOTHERAPEUTIC MEDICATIONS IN NON-TRADITIONAL AMBULATORY SETTINGS." VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1986.

Full text

Abstract:

Background: Cancer is the second leading cause of death in economically developed countries. The use and availability of oral treatment for cancer has increased dramatically in the past 10 years. Few studies have described the use of oral chemotherapy in non-traditional ambulatory settings by health care professionals across different specialties. Objective: The purpose of this study is to describe the usage of oral chemotherapeutic medications in ambulatory settings. Methods: Cross sectional study of 2007 NAMCS Survey analysis involving 21,761 subjects aged 18 years and above with cancer wh

APA, Harvard, Vancouver, ISO, and other styles

50

Ferrari, Mathieu. "Characterisation of scFv A7 reactivity and development of a novel bispecific antibody for targeted therapies in Rheumatoid Arthritis." Thesis, Queen Mary, University of London, 2014. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8975.

Full text

Abstract:

Despite the success of current biological agents, achievement of broader efficacy and improved safety profile remains an unmet need in rheumatoid arthritis therapy. Neovasculogenesis plays a vital role in the progression and perpetuation of rheumatoid arthritis and significant evidence has demonstrated molecular heterogeneity within the endothelium (MVE) of different tissues. The heterogeneity of the synovial MVE can be exploited for the development of organ-specific therapeutic and diagnostic reagents. A novel recombinant antibody fragment, scFv A7, with specificity for human arthritic synovi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!